<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61643">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303431</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-A-U157</org_study_id>
    <nct_id>NCT02303431</nct_id>
  </id_info>
  <brief_title>Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a
      single dose of edoxaban will be given to pediatric subjects who require anticoagulant
      therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to
      the body (pharmacodynamics), and to compare if these effects are similar to those observed
      in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, open-label, multiple-center study in pediatric patients from 0 to &lt; 18 years of
      age. Patients will receive a single dose of edoxaban to match either the 30 mg (low dose) or
      the 60 mg (high dose) exposure in adults. Exact doses will be selected during the study on
      the basis of PK modeling of emerging data. If unanticipated exposures are observed, the
      target doses may be modified to best match expected exposure response relationships observed
      in adults.

      Enrollment in the study will start with the low dose, highest age group (adolescents) and
      will continue from low to high dose in each age group and from higher to lower age groups.
      Enrollment in the next dose/age cohort will begin after 50% of the subjects have completed
      the previous dose/age cohort.

      Age cohorts and dose groups: (6 participants each in low and high dose groups, for a total
      of 12 participants per age cohort)

        -  12 to &lt; 18 years of age

        -  6 to &lt;12 years of age

        -  2 to &lt;6 years of age

        -  6 months to &lt;2 years of age

        -  0 to &lt;6 months of age
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK)- Apparent systemic clearance (CL/F)</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK- Apparent volume of distribution (V/F)</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK- Area under the concentration-time curve (AUC) for edoxaban and metabolites</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings); metabolites include D21-2393, D21-3231, D21-1402, and D21-2135</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK- Metabolite/parent ratios for AUC</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings); metabolites include D21-2393, D21-3231, D21-1402, and D21-2135</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PDy)- Mean prothrombin time (PT)</measure>
    <time_frame>Predose and within 36 hours postdose</time_frame>
    <description>Predose and immediately after simultaneously scheduled PK blood samples, using a dosing windows approach: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 6 blood samplings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDy- Mean activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Predose and within 36 hours postdose</time_frame>
    <description>Predose and immediately after simultaneously scheduled PK blood samples, using a dosing windows approach: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 6 blood samplings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDy- Mean anti-Factor Xa (FXa)</measure>
    <time_frame>Predose and within 36 hours postdose</time_frame>
    <description>Predose and immediately after simultaneously scheduled PK blood samples, using a dosing windows approach: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 6 blood samplings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety- Number of participants with clinically significant changes in safety assessments</measure>
    <time_frame>Predose to Day 10</time_frame>
    <description>Safety assessments: adverse events, physical examination findings, vital signs, clinical laboratory assessments, and urinalysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean palatability score for the liquid formulation on a 100 mm visual analog scale (VAS)</measure>
    <time_frame>within 30 minutes after dosing</time_frame>
    <description>Bitterness, sweetness, and overall taste or aroma will be assessed by participants receiving the liquid oral suspension or their guardians using visual analog scale (VAS) scores</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 to &lt; 18 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 to &lt; 18 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 to &lt; 12 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 to &lt; 12 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 to &lt; 6 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 to &lt; 6 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months to &lt;2 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months to &lt;2 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0 to 6 months of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0 to 6 months: edoxaban high dose group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban low dose</intervention_name>
    <description>Edoxaban low dose</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_label>Cohort 4a</arm_group_label>
    <arm_group_label>Cohort 5a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban high dose</intervention_name>
    <description>Edoxaban high dose</description>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_label>Cohort 3b</arm_group_label>
    <arm_group_label>Cohort 4b</arm_group_label>
    <arm_group_label>Cohort 5b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is a pediatric subject requiring anticoagulant therapy

          -  Will abstain from the use of nonsteroidal anti-inflammatory drugs (such as
             ibuprofen), and other antiplatelet and anticoagulant agents (except for aspirin) from
             24 hours prior to edoxaban dose until after the last PK sample is collected

          -  Will follow food and concomitant medication restrictions

        Exclusion Criteria:

          -  Any major or clinically relevant unexplained bleeding during prior anticoagulant
             therapy

          -  History of abnormal bleeding or coagulation within last 6 months prior to study drug
             administration

          -  Renal function with glomerular filtration rate (GFR) less than 50% of normal for age
             and size

          -  Malabsorption disorders (e.g., cystic fibrosis or short bowel syndrome)

          -  Hepatic disease associated with coagulopathy leading to a clinically relevant
             bleeding risk, alanine transaminase (ALT) &gt; 5 times the upper limit of normal (ULN)
             or total bilirubin &gt; 2 times the ULN with direct bilirubin &gt; 20% of the total
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Melino, MSc, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo UK Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peggy Hew, M.Sc.</last_name>
    <phone>+44 208 563 5962</phone>
    <email>p.hew@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>22710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <zip>21500</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Giza</city>
        <zip>12613</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rome</city>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vitoria-Gasteiz</city>
        <zip>101010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>October 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Pharmacokinetics (PK)</keyword>
  <keyword>Pharmacodynamics (PDy)</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
